GPRC6A

Across TCGA pan-cancer cohorts, GPRC6A Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated GPRC6A data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GPRC6A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPRC6A expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, UCEC, and COAD are the cancer types where GPRC6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.249	0.542	.005	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.297	<.001	34	view →
COAD	OS	Median	II,III,IV	0.224	0.792	.001	18	view →
SKCM	OS	Median	II,III,IV	0.965	0.818	<.001	15	view →
BRCA	OS	Median	III,IV	0.514	0.906	.001	10	view →
SARC	DFS	Median	All	0.173	0.612	.020	6	view →
SCLC	DFS	Median	III,IV	0.263	0.586	.023	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.423	.037	4	view →
LUAD	OS	Median	III,IV	0.205	0.687	.015	3	view →
LGG	OS	Median	All	0.659	0.908	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

GPRC6A–OV (DFS)

Open the OV breakdown →